Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp56444_8k.htm |
Exhibit 99.1
Press Release |
 |
| www.shire.com |
Block Listing Six Monthly Return
May 26, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG)
| Name of applicant: | Shire plc | |||
| Name of scheme: | 2000 Executive Share Option Scheme | |||
| Period of return: | From: | November 23, 2014 | To: | May 22, 2015 |
| Balance of unallotted securities under scheme(s) from previous return: | 3,406,623 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | Nil | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 3,406,623* | |||
*There are no further awards outstanding under the 2000 Executive Share Option Scheme and therefore these shares have been cancelled.
| Name of applicant: | Shire plc | |||
| Name of scheme: | Shire Sharesave Scheme | |||
| Period of return: | From: | November 23, 2014 | To: | May 22, 2015 |
| Balance of unallotted securities under scheme(s) from previous return: | 207,758 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 4,207 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 203,551 | |||
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
| Name of applicant: | Shire plc | |||
| Name of scheme: | Shire Portfolio Share Plan | |||
| Period of return: | From: | November 23, 2014 | To: | May 22, 2015 |
| Balance of unallotted securities under scheme(s) from previous return: | 1,138,214 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 2,000,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 1,353,145 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,785,069 | |||
| Name of applicant: | Shire plc | |||
| Name of scheme: | Shire Employee Stock Purchase Plan | |||
| Period of return: | From: | November 23, 2014 | To: | May 22, 2015 |
| Balance of unallotted securities under scheme(s) from previous return: | 524,710 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 2,373 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 522,337 | |||
| Name of applicant: | Shire plc | |||
| Name of scheme: | Shire Long Term Incentive Plan 2015 | |||
| Period of return: | From: | May 13, 2015 | To: | May 22, 2015 |
| Balance of unallotted securities under scheme(s) from previous return: | Nil | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 3,000,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | Nil | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 3,000,000 | |||
2
| Name of contact: | Tony Guthrie, Deputy Company Secretary |
| Address of contact: |
Hampshire International Business Park
Basingstoke, Hampshire, RG24 8EP |
| Telephone number of contact: | 01256 894746 |
For further information please contact:
| Investor Relations | ||
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com
3